Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:09 PM ET 8-K
M&A Deal KLX Energy Services Holdings, Inc. KLXE

KLX Energy Services Holdings Signs $16.7M M&A Deal with Wolf Pack Rentals, LLC

KLX Energy Services Holdings, Inc. provided pro forma financial statements following its acquisition of assets from Wolf Pack Rentals, LLC for $16.7 million. The deal, which closed on June 2, 2026, was funded with $14.1 million in cash at closing and $2.7 million in deferred payments (net present value) payable in cash or stock. The filing provides unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2026, to reflect the impact of the acquisition.

Value
$16.7M
Counterparty
Wolf Pack Rentals, LLC
4:09 PM ET 8-K
Clinical Trial Data Moleculin Biotech, Inc. MBRX

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.

Counterparty
The University of Texas MD Anderson Cancer Center
4:08 PM ET 8-K
Capital Raise Pacific Biosciences of California, Inc. PACB

Pacific Biosciences of California Capital Raise

Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.

Counterparty
Allen & Company LLC
4:08 PM ET 8-K
Regulatory Approval Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
4:07 PM ET 8-K
Divestiture Braemar Hotels & Resorts Inc. BHR

Braemar Hotels & Resorts Divestiture to Ashford Inc. for $480M

Braemar Hotels & Resorts has completed its transition to a self-managed REIT by terminating its advisory agreement with Ashford Inc. and its affiliates. In connection with the internalization, the company incurred a $480 million liability for termination payments triggered by previous asset sales, which it is settling through cash payments and the transition of management functions in-house.

Value
$480M
Counterparty
Ashford Inc.
4:07 PM ET 8-K
Capital Raise Newton Golf Company, Inc. NWTG

Newton Golf Company Capital Raise of $1.2M

Newton Golf Company closed a $1.2 million third tranche of its ongoing private placement, issuing 967,739 shares of common stock at $1.24 per share. The investors included company director Brett Hoge and three other parties. This brings the total raised under the $5 million private placement facility to approximately $2.47 million across three tranches.

Value
$1.2M
Counterparty
November Common Stock Investors
4:06 PM ET 8-K
M&A Deal Independence Realty Trust, Inc. IRT

Independence Realty Trust M&A Deal with Centerspace

Stockholders of Independence Realty Trust (IRT) and shareholders of Centerspace have approved the previously announced merger between the two multifamily REITs. Under the terms of the agreement, Centerspace shareholders will receive 3.800 shares of IRT common stock for each share owned. The deal creates a leading multifamily REIT focused on high-growth non-gateway markets in the Sunbelt, Midwest, and Mountain West regions.

Counterparty
Centerspace
4:06 PM ET 8-K
Capital Raise FrontView REIT, Inc. FVR

FrontView REIT Capital Raise of $30M

FrontView REIT, Inc. issued 300,000 shares of Series A Convertible Preferred Stock at $100.00 per share, raising gross proceeds of approximately $30.0 million. The private placement was made to a group of institutional investors including Maewyn FVR II LP and Petrus Special Opportunities Fund under a previously established investment agreement.

Value
$30M
Counterparty
Maewyn FVR II LP, Rebound Investment, LP and Petrus Special Opportunities Fund, L.P.
3:50 PM ET 8-K
Divestiture Exicure, Inc. XCUR

Exicure Divestiture to GPCRT Inc. for $4.8M

Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.

Value
$4.8M
Counterparty
GPCRT Inc.
3:01 PM ET 8-K
M&A Deal Curaleaf Holdings, Inc. CURLF

Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.

Curaleaf Holdings announced it has received all required competition law clearances from regulators in Germany and Canada for its proposed acquisition of Aurora Cannabis Inc. The company's enhanced premium bid to acquire all outstanding shares of Aurora remains open until December 4, 2026, as it competes against a rival proposal from Organigram.

Counterparty
Aurora Cannabis Inc.
9:01 AM ET 8-K
Contract Win Safe Pro Group Inc. SPAI

Safe Pro Group Wins $2.5M Contract from U.S. Army

Safe Pro Group Inc. was awarded a $2.5 million U.S. Government Prime Contract to provide its Super Intelligence (SI) threat detection and mapping software for the U.S. Army's Abrams Tanks. The company will team with Anduril Industries to integrate its software onto the Ghost-X drone platform to enable real-time identification and geolocation of over 150 types of explosive threats.

Value
$2.5M
Counterparty
U.S. Army
8:41 AM ET 8-K
Clinical Trial Data Azitra, Inc. AZTR

Azitra Clinical Trial Data

Azitra announced positive ex vivo human skin model data for its ATR-COSF program, showing a 56% reduction in wrinkles and improved skin elasticity. The company plans to initiate a first-in-human study for the filaggrin-based topical cosmetic with initial results expected by year-end 2026. Additionally, the company provided updates on its ATR-04 Phase 1/2 trial, which has been expanded to include patients with rashes from KRAS and MEK inhibitors.

8:34 AM ET 8-K
Capital Raise Rackspace Technology, Inc. RXT

Rackspace Technology Capital Raise of $66M

Rackspace Technology raised approximately $66 million through private placements of its common stock. The company issued 18,181,816 shares to Voss Capital for $50 million and an additional 5,818,181 shares to other purchasers for $16 million to fund general corporate purposes and GPU-related growth initiatives.

Value
$66M
Counterparty
Voss Capital, LP
8:31 AM ET 8-K
Licensing Deal Ocugen, Inc. OCGN

Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M

Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.

Value
$7.1M
Counterparty
Celairis Therapeutics Holdings Pty Ltd
Term
20 years
8:22 AM ET 8-K
M&A Deal Maxcyte, Inc. MXCT

Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC

MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.

Value
$125M
Counterparty
Akron BioProducts LLC

“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”

Maher Masoud, President and CEO of MaxCyte
8:06 AM ET 8-K
Capital Raise PDS Biotechnology Corp PDSB

PDS Biotechnology Capital Raise of $3.9M

NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.

Value
$3.9M
Counterparty
NantWorks
8:01 AM ET 8-K
Clinical Trial Data PepGen Inc. PEPG

PepGen Clinical Trial Data

PepGen reported positive topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 trial for PGN-EDODM1 in patients with myotonic dystrophy type 1. The data demonstrated a mean splicing correction of 46.5%, the highest reported to date in a multiple dose study, alongside functional improvements and a generally well-tolerated safety profile.

“The positive 10 mg/kg cohort results we announced today were made possible by our team’s focused execution. We are very confident in PGN-EDODM1’s potential to deliver meaningful benefit to the DM1 community, and our company ended the quarter in a strong position to advance the program to the third and highest dose cohort, which is fully enrolled.”

James McArthur, Ph.D., President and Chief Executive Officer
8:00 AM ET 8-K
Partnership AST SpaceMobile, Inc. ASTS

AST SpaceMobile Partnership with Rakuten Group, Inc. Worth $1B

AST SpaceMobile and Rakuten Group have established a joint venture named Rakuten AST, Inc. to build a direct-to-device satellite communications network in Japan. The project is supported by approximately $1 billion (148 billion yen) in funding from Japan's Ministry of Internal Affairs and Communications (MIC) to deploy a sovereign mid-band satellite constellation. AST SpaceMobile will supply the satellites for the network, which aims to commence domestic operations by March 2029.

Value
$1B
Counterparty
Rakuten Group, Inc.
Term
3 years
7:42 AM ET 8-K
Clinical Trial Data Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.

7:33 AM ET 8-K
M&A Deal Lci Industries LCII

Lci Industries M&A Deal with Patrick Industries, Inc.

LCI Industries announced that its Board of Directors unanimously rejected a revised unsolicited acquisition proposal from Monomoy Capital Partners for $104.50 per share in cash. The Board determined the offer substantially undervalues the company and reiterated its support for the pending merger with Patrick Industries, which it believes offers superior long-term value.

Counterparty
Patrick Industries, Inc.

“The LCI Board of Directors takes seriously its responsibility to best serve the interests of all LCI shareholders, and it is through that lens that we evaluate opportunities to maximize shareholder value, including proposals to merge with or acquire LCI.”

Ginnie Henkels, Chair of the Board of Directors

“Monomoy’s revised proposal is a modest increase to its initial offer and remains nowhere near LCI’s standalone value or the value creation opportunity of our combination with Patrick.”

Ginnie Henkels, Chair of the Board of Directors
7:11 AM ET 8-K
Divestiture Scholar Rock Holding Corp SRRK

Scholar Rock Holding Divestiture to BioNTech US Inc. for $205M

Scholar Rock agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to BioNTech US Inc. for $205 million in cash. The voucher was originally awarded by the FDA following the approval of ISEMBYLD for the treatment of spinal muscular atrophy. The transaction is subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.

Value
$205M
Counterparty
BioNTech US Inc.

“The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA. We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.”

David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
7:01 AM ET 8-K
M&A Deal SUNation Energy, Inc. SUNE

SUNation Energy M&A Deal with Suniva, Inc.

SUNation Energy provided a status update on its pending reverse merger with Suniva, Inc., noting that Suniva has commenced construction on a new 4.5 GW solar cell manufacturing facility in South Carolina. The $600 million expansion project is expected to increase the combined company's total U.S. manufacturing capacity to 5.5 GW by 2028. The merger, originally announced in June 2026, will result in Suniva becoming a wholly owned subsidiary of SUNation.

Counterparty
Suniva, Inc.
6:45 AM ET 8-K
Capacity Expansion Nova Minerals Corp NVA

Nova Minerals Capacity Expansion

Nova Minerals confirmed a 216,000 tonnes per annum (tpa) processing capacity for its newly acquired plant at Port MacKenzie, Alaska. The facility is designed to serve as a multi-commodity critical minerals hub for the Estelle Project and third-party sources, with potential refined antimony production of up to 20,000 tpa. The project is supported by a $43.4 million Department of War (DoW) grant for initial pilot-scale production.

6:05 AM ET 8-K
Product Launch Cycurion, Inc. CYCU

Cycurion Product Launch

Cycurion launched Habit, an AI-driven security operations center (SOC) designed to identify and remediate threats by learning behavioral baselines for identities and workloads. The launch marks the company's strategic repositioning as a predictive cybersecurity firm and is the first major release in its new predictive intelligence portfolio.

6:04 AM ET 8-K
Capital Raise TEN Holdings, Inc. XHLD

TEN Holdings Capital Raise of $2M

TEN Holdings, Inc. closed a registered direct offering of 3,389,831 shares of common stock at a price of $0.59 per share. The transaction generated gross proceeds of approximately $2.0 million before expenses. The company intends to use the net proceeds for working capital and general corporate purposes.

Value
$2M
6:04 AM ET 8-K
Capital Raise Sixth Street Specialty Lending, Inc. TSLX

Sixth Street Specialty Lending Capital Raise

Sixth Street Specialty Lending entered into equity distribution agreements with several sales agents to establish an at-the-market (ATM) offering program. The company may issue and sell shares of common stock having an aggregate offering price of up to $100 million. Proceeds are intended for general corporate purposes, including new investments and debt repayment.

Counterparty
RBC Capital Markets, LLC
6:04 AM ET 8-K/A
M&A Deal Enhanced Group Inc. ENHA

Enhanced Group M&A Deal with DEAG Deutsche Entertainment Aktiengesellschaft

Enhanced Group Inc. entered into exchange agreements with several investment groups to acquire shares of DEAG Deutsche Entertainment Aktiengesellschaft, a German live-entertainment company. In exchange for 3,165,659 DEAG shares, Enhanced Group will issue 1,815,505 shares of its Class A Common Stock to holders including Galaxy Group Funding, Apeiron 101 Ltd., and B72 Ventures GmbH.

Counterparty
DEAG Deutsche Entertainment Aktiengesellschaft
6:03 AM ET 8-K
Bankruptcy & Restructuring Mercer International Inc. MERC

Mercer International Bankruptcy & Restructuring

Mercer International Inc. filed for Chapter 11 bankruptcy protection in the Southern District of Texas to implement a prepackaged restructuring plan. The restructuring includes a $420 million backstopped rights offering of new money senior secured notes and the cancellation of existing common stock, with noteholders receiving 91.5% of the new equity. The company has already secured support from a majority of its 2028 and 2029 senior noteholders through restructuring support agreements.

Counterparty
Required Consenting Senior Noteholders
6:02 AM ET 8-K
Bankruptcy & Restructuring Lzg International, Inc. LZGI

Lzg International Bankruptcy & Restructuring

LZG International announced that its board has determined the company has no practical alternative but to wind down its affairs and recommends an assignment for the benefit of creditors under Florida law. The company reports that its liabilities of approximately $12.88 million substantially exceed its assets and it has no operating business. Additionally, the company will consent to the SEC's revocation of its common stock registration due to its inability to fund required audited financial statements.

6:02 AM ET 8-K
M&A Deal Bhav Acquisition Corp BHAV

Bhav Acquisition M&A Deal with Nemi Corp.

BHAV Acquisition Corp, a special purpose acquisition company (SPAC), has entered into a definitive business combination agreement with Nemi Corp., a Texas-based physical AI and hardware company. Upon closing, BHAV will become a wholly-owned subsidiary of Nemi (the surviving public company), with the transaction expected to close in the first quarter of 2027 subject to shareholder and regulatory approvals.

Counterparty
Nemi Corp.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.